Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Mackenzie Financial Corp

Key Points

• Mackenzie Financial Corp significantly increased its stake in Lantheus Holdings, owning approximately 0.73% of the company after acquiring an additional 280,381 shares, now valued at $48.55 million.
• The recent quarterly earnings report showed Lantheus missed EPS estimates with $1.53, compared to the expected $1.64, and reported revenue of $372.76 million against a forecast of $377.37 million.
• Despite the earnings miss, analysts generally maintain a positive outlook with multiple buy ratings, and a consensus price target of $131.20, indicating expected growth for the company.

Mackenzie Financial Corp raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 129.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 497,437 shares of the medical equipment provider's stock after acquiring an additional 280,381 shares during the period. Mackenzie Financial Corp owned approximately 0.73% of Lantheus worth $48,550,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Janus Henderson Group PLC increased its holdings in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after buying an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after purchasing an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC boosted its stake in shares of Lantheus by 39.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after purchasing an additional 273,838 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Down 1.6%

Shares of LNTH traded down $1.16 during mid-day trading on Friday, hitting $70.04. The company's stock had a trading volume of 50,893 shares, compared to its average volume of 1,003,339. The company's 50-day moving average is $77.71 and its 200-day moving average is $88.13. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.21. The firm has a market capitalization of $4.85 billion, a price-to-earnings ratio of 19.90 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.69 EPS. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent analyst reports. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, B. Riley lowered their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $131.20.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.